Cyclophosphamide: new approaches for systemic lupus erythematosus

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a severe autoimmune disease with significant organ involvement.
• Cyclophosphamide is the established treatment for severe, organ-threatening SLE, especially lupus nephritis and CNS lupus.
• Balancing efficacy with toxicity is crucial in managing SLE.

Purpose of the Study:

• To review the efficacy and toxicity of cyclophosphamide in treating severe SLE.
• To compare intravenous and oral cyclophosphamide regimens.
• To contrast traditional cyclophosphamide use with emerging therapeutic strategies.

Main Methods:

• Retrospective comparison of intravenous and oral cyclophosphamide.
• Meta-analysis of cyclophosphamide with oral prednisone versus prednisone alone.
• Review of clinical trial data on cyclophosphamide for lupus nephritis.
• Discussion of toxicity profiles, including infection, gonadal failure, and malignancy.

Main Results:

• Remission rates of 73% (oral) and 90% (intravenous) observed retrospectively over two years.
• Intravenous cyclophosphamide plus oral prednisone demonstrated superior efficacy compared to oral prednisone alone in a meta-analysis.
• Cyclophosphamide has proven efficacy in lupus nephritis, but carries risks of infection, gonadal failure, and malignancy.

Conclusions:

• Cyclophosphamide remains a widely used treatment for severe SLE, particularly renal and CNS manifestations.
• Despite challenges from newer agents like mycophenolate mofetil and biologics, cyclophosphamide's efficacy is well-established.
• This review examines traditional intravenous pulse cyclophosphamide, its toxicity, and newer treatment alternatives.